Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Cancer Institute, part of the National Institutes of Health, is seeking grant applications to advance and validate emerging technologies for basic and clinical cancer research under the R33 Clinical Trial Not Allowed funding opportunity. The work focuses on further development and rigorous technical validation of novel technologies for molecular or cellular characterization of cancer and for improved handling and quality control of biospecimens used in cancer research. Eligible projects should build on supportive preliminary data, address cancer-relevant use cases, and demonstrate quantifiable performance improvements; applications proposing hypothesis-driven research that merely uses existing technologies are not responsive. The opportunity includes about 13 awards totaling an estimated $5.9 million, with budgets capped at $300,000 per year for up to three years, and no clinical trials are allowed. Applications are due November 10, 2026, and the grant contact is NCI-IMAT@nih.gov.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.